- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Glenmark Pharmaceuticals Limited — Updates, 21-03-2026: Press Release
21-03-2026 | 12:15 am
21-03-2026 | 12:15 am
Glenmark launched GLIPIQ® (semaglutide) in India for Type 2 Diabetes, targeting wider access. Weekly treatment starts at ₹325, setting a new benchmark in affordability for GLP-1 therapy. This strategic move could significantly expand market penetration.
No comments yet. Be the first to comment!